Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GTBP with free AI briefings, catalyst countdowns, and dilution alerts.

GTBP · GT Biopharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $3.54, 51% below $7.18, its close on the day of its Sep 21 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$5M Cash on Hand
4.4mo Cash Runway
Follow GTBP by email Get an email when GTBP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GTBP, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Fc-Gamma Receptor III High-risk Myelodysplastic Syndromes Phase 1/2 · NCT03214666 Terminated
Anti-B7-H3/IL-15/Anti-CD16 Trispecific Natural… Tri-specific Killer Engager Phase 1 · NCT07541573 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GTBP holds $5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.4M/quarter from operations, an estimated runway of 4.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GTBP files for a raise →

👥 Who Owns GTBP

Insiders 0% Other 5%+ holders 8.4% Institutions (35 holders) 7.4% Public and other holders 84.2%
HolderTypeShares% of sharesAs of
RainForest Partners, LLC 5%+ holder (13G) 180,258 8.43% 2026-09-15

Share count 2,137,240 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GTBP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GTBP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.